Global Antifungal Agents Market 2025-2035

Description

List of Tables

Global Antifungal Agents Market Size, Share & Trends Analysis by Drug Class (Polyene, Echinocandins, Allylamines, and Azole), by Dosage Type (Powder, Ointment, and Drugs) and by Route of Administration (Parenteral, Topical, and Oral) Forecast Period (2025-2035)

Industry Overview

Antifungal agents market was valued at $16.3 billion in 2024 and is projected to reach $24.6 billion by 2035, growing at a CAGR of 3.9% during the forecast period (2025-2035). The market growth is driven by the increasing incidence of fungal infections, a growing population of immunocompromised individuals, and advancements in drug development. Key factors influencing this growth include the rising prevalence of hospital-acquired infections, expanding healthcare access in developing regions, and increased awareness about fungal diseases. However, challenges such as the growing concern of antifungal resistance and the safety profile of some systemic agents may limit market growth.

Market Dynamics

Rising Prevalence of Immunocompromised and Chronic-Disease Populations

Increasing numbers of cancer patients on chemotherapy, organ-transplant recipients, people living with HIV, and a growing elderly population are driving a higher incidence of opportunistic and systemic fungal infections (e.g., invasive candidiasis, aspergillosis). That larger susceptible pool increases both treatment volume and demand for newer, more effective agents across hospital and outpatient settings.

Antifungal Resistance and Urgent Pipeline Need

Resistance to older classes (some azoles and polyenes) together with climate-driven emergence of new fungal threats has pushed funders and biotech to accelerate clinical development for novel mechanisms (e.g., olorofim). This creates short-term investment and long-term growth as novel drugs move through late-stage trials and potentially capture premium pricing for hard-to-treat invasive infections.

Improved Diagnostics, Access, and Outpatient Treatment Trends

Better fungal diagnostics (faster labs, biomarkers) and expanding outpatient/primary-care management (oral therapies, OTC topical products) shift treatment earlier and increase market uptake. In parallel, expanding healthcare infrastructure in emerging markets and rising awareness of superficial fungal diseases (dermatophytosis, vulvovaginal candidiasis) enlarge the addressable market beyond hospitals.

Market Segmentation

Based on the drug class, the market is segmented into polyenes, echinocandins, allylamines, and azoles.
Based on the dosage type, the market is segmented into powder, ointment, and drugs.
Based on the route of administration, the market is segmented into parenteral, topical, and oral.

The Azole Segment to Grow at a Considerable Market Share

The Azole drug class segment leads the global antifungal agents' market with the largest share and is expected to maintain its dominance throughout the forecast period. Azoles such as fluconazole, itraconazole, and voriconazole are preferred due to their broad-spectrum efficacy, safety, and affordability. They are effective against a wide range of fungal infections like candidiasis, aspergillosis, and dermatophytosis, and are available in multiple formulations, oral, topical, and parenteral, enhancing their accessibility and convenience. The growing use of oral azoles for outpatient treatments, coupled with advancements in next-generation triazoles offering improved potency and fewer side effects, further strengthens their market leadership. Increasing incidences of fungal infections among immunocompromised patients and expanding access to antifungal therapies in developing regions continue to drive the dominance of azoles in the global market.

Oral: A Key Segment in Market Growth

The oral route of administration segment is the key growth driver in the global antifungal agents market due to its high patient compliance, convenience, and broad therapeutic coverage. Oral antifungal drugs such as fluconazole and itraconazole are preferred for both superficial and systemic infections, allowing easy transition from hospital to home care while reducing treatment costs. Advances in formulation technology have improved drug efficacy and safety, further boosting adoption. Additionally, the growing prevalence of fungal infections and expanding access to retail pharmacies in emerging markets are fuelling demand for oral antifungal medications, making this segment the fastest-growing and most widely used in the market.

Regional Outlook

The global antifungal agents market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US dominates the global antifungal agents market, accounting for the largest revenue share owing to its well-established healthcare infrastructure, high awareness of fungal infections, and the strong presence of leading pharmaceutical companies. The country reports a significant burden of both superficial and invasive fungal infections, particularly among immunocompromised patients, including individuals undergoing organ transplants, cancer treatments, and those with HIV/AIDS. The increasing prevalence of Candida auris and Aspergillus infections has further driven the need for advanced antifungal therapies. The U.S. Food and Drug Administration (FDA) actively supports the approval of innovative antifungal drugs, such as ibrexafungerp and rezafungin, enhancing market availability of novel treatment options and promoting healthy competition among manufacturers. Additionally, major pharmaceutical players such as Pfizer Inc., Merck & Co., Astellas Pharma, and Gilead Sciences have strong product portfolios and R&D investments in antifungal drug development, ensuring continuous innovation in treatment options.

Moreover, the growing awareness among healthcare professionals and patients, coupled with improved diagnostic facilities, has significantly increased early detection and treatment rates of fungal infections in the US. The availability of insurance coverage and advanced hospital-based care has additionally contributed to higher antifungal drug consumption. The expansion of outpatient treatment options, especially oral formulations, further strengthens the country's market dominance. Furthermore, robust clinical research, high healthcare spending, and rapid adoption of newly approved antifungal drugs continue to keep the US at the forefront of global market growth. Overall, the combination of a strong pharmaceutical ecosystem, advanced medical infrastructure, and proactive regulatory support has established the United States as the leading country in the global antifungal agents market.

Market Players Outlook

The major companies operating in the global antifungal agents market include GlaxoSmithKline plc (GSK), Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

In September 2023, BDR Pharma launched Zisavel capsules, a generic drug for fungal infections, at one-third of the cost of current therapies. The initiative aims to make isavuconazole as affordable as voriconazole and posaconazole, ensuring affordable treatment for patients.

The Report Covers:

Market value data analysis for 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global antifungal agents market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2024041

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Antifungal Agents Market Sales Analysis - Drug Class | Dosage Type | Route of Administration ($ Million)
Antifungal Agents Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Antifungal Agents Market Trends
- 2.2.2. Market Recommendations
2.3. Porter's Five Forces Analysis for the Antifungal Agents Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Antifungal Agents Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Antifungal Agents Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For Global Antifungal Agents Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Antifungal Agents Market Revenue and Share by Manufacturers
Antifungal Agents Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Abbott Laboratories
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Bayer AG
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. F. Hoffmann-La Roche Ltd.
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. GlaxoSmithKline (GSK) plc
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Pfizer Inc.
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Antifungal Agents Market Sales Analysis by Drug Class($ Million)

5.1. Polyene
5.2. Echinocandins
5.3. Allylamines
5.4. Azole

6. Global Antifungal Agents Market Sales Analysis by Dosage Type ($ Million)

6.1. Powder
6.2. Ointment
6.3. Drugs

7. Global Antifungal Agents Market Sales Analysis by Route of Administration ($ Million)

7.1. Parenteral
7.2. Topical
7.3. Oral

8. Regional Analysis

8.1. North American Antifungal Agents Market Sales Analysis - Drug Class| Dosage Type | Route of Administration ($ Million)
Macroeconomic Factors for North America
- 8.1.1. United States
- 8.1.2. Canada
8.2. European Antifungal Agents Market Sales Analysis - Drug Class| Dosage Type | Route of Administration ($ Million)
Macroeconomic Factors for Europe
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
8.3. Asia-Pacific Antifungal Agents Market Sales Analysis - Drug Class| Dosage Type | Route of Administration ($ Million)
Macroeconomic Factors for Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 8.3.7. Rest of Asia-Pacific
8.4. Rest of the World Antifungal Agents Market Sales Analysis - Drug Class| Dosage Type | Route of Administration ($ Million)
Macroeconomic Factors for the Rest of the World
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa

9. Company Profiles

9.1. Pfizer Inc.
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
9.2. Novartis AG
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
9.3. Merck & Co., Inc.
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
9.4. Bayer AG
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
9.5. GlaxoSmithKline plc
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
9.6. Sanofi S.A.
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
9.7. Astellas Pharma Inc.
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
9.8. Abbott Laboratories
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
9.9. Gilead Sciences, Inc.
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
9.10. Aurobindo Pharma / large generic producers
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
9.11. Glenmark Pharmaceuticals
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
9.12. Sun Pharmaceutical Industries Ltd.
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
9.13. Cipla Ltd.
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
9.14. Hikma Pharmaceuticals
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies
9.15. Basilea Pharmaceutica Ltd.
- 9.15.1. Quick Facts
- 9.15.2. Company Overview
- 9.15.3. Product Portfolio
- 9.15.4. Business Strategies
9.16. SCYNEXIS, Inc.
- 9.16.1. Quick Facts
- 9.16.2. Company Overview
- 9.16.3. Product Portfolio
- 9.16.4. Business Strategies
9.17. Mycovia Pharmaceuticals
- 9.17.1. Quick Facts
- 9.17.2. Company Overview
- 9.17.3. Product Portfolio
- 9.17.4. Business Strategies
9.18. F2G Ltd.
- 9.18.1. Quick Facts
- 9.18.2. Company Overview
- 9.18.3. Product Portfolio
- 9.18.4. Business Strategies
9.19. Zydus Cadila
- 9.19.1. Quick Facts
- 9.19.2. Company Overview
- 9.19.3. Product Portfolio
- 9.19.4. Business Strategies
9.20. Teva Pharmaceutical Industries
- 9.20.1. Quick Facts
- 9.20.2. Company Overview
- 9.20.3. Product Portfolio
- 9.20.4. Business Strategies